ABSTRACT
Background Lung clearance index (LCI) quantifies global ventilation inhomogeneity, a sensitive biomarker of airway function in cystic fibrosis (CF) lung disease.
Objectives We examined the association of LCI with the risk of death or lung transplantation (LTX) in individuals with CF.
Methods We performed a retrospective analysis in a cohort of individuals with CF aged ≥ five years with available LCI and FEV1 measurements between 1980 and 2006. Outcome was time until death or LTX. We applied Cox proportional hazard regressions using the earliest available LCI and FEV1 values and adjusted for demographic and clinical variables. For sensitivity analyses, we used the mean of the first three LCI and FEV1 measurements, stratified the cohort based on age, and investigated individuals with normal FEV1.
Results In total, 237 individuals with CF aged mean (range) 13.9 (5.6–41.0) years were included. This time-to-event analysis accrued 3813 person-years, 94 (40%) individuals died or received LTX. Crude hazard ratios [95% CI] were 1.04 [1.01–1.06] per one z-score increase in LCI and 1.25 [1.11–1.41] per one z-score decrease in FEV1. After adjusting LCI and FEV1 mutually in addition to sex, age, BMI and the number of hospitalisations, hazard ratios were 1.04 [1.01-1.07] for LCI, and 1.12 [0.95-1.33] for FEV1. Sensitivity analyses yielded similar results and using the mean LCI strengthened the associations.
Conclusions Increased ventilation inhomogeneity is associated with greater risk of death or LTX. Our data support LCI as novel surrogate of survival in individuals with CF.
TAKE HOME MESSAGE Lung clearance index (LCI) is a measure of global ventilation inhomogeneity which increases early during the course of Cystic Fibrosis (CF) lung disease. This study shows that LCI is predictive of death or lung transplantation in individuals with CF.
Study registration number NCT04016194
Competing Interest Statement
Dr. Singer reports grants from Swiss Society for Cystic Fibrosis, during the conduct of the study. Dr. Latzin reports grants from Vertex Pharmaceuticals Incorporated, during the conduct of the study.
Clinical Trial
NCT04016194
Funding Statement
This project was funded by unrestricted educational grants from Vertex Pharmaceuticals Incorporated, Swiss National Science Foundation (SNSF) and Swiss Society of Cystic Fibrosis (CFCH).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was given by the local ethics committee (KEK BE 2018-01642). Written informed consent from survivors and relatives of the individuals who died was not required from the ethics committee and therefore not obtained for this study. Full names and affiliations of all Ethics Committees / Institutional Review Boards: Kantonale Ethikkommission fuer die Forschung (KEK) - Commission cantonale d ethique de la recherche. Murtenstrasse 31, 3010 Bern, Switzerland. T +41 31 633 70 70 F +41 31 633 70 71 www.be.ch/kek Ethical approval was given on November 27, 2018. Project-ID 2018-01642. Sponsor & Investigator: Florian Singer. KEK President Prof. Dr. med. Christian Seiler. KEK Vice President Dr. sc. nat. Dorothy Pfiffner
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos